Pharmaceuticals News and Research

RSS

Akorn's consolidated revenue for fourth quarter 2013 increases 19% to $85 million

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the fourth quarter and year-ended December 31, 2013.

3 Mar 2014

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare.

3 Mar 2014

First Edition: March 3, 2014

Today's headlins include stories detailing ongoing challenges with state-run exchanges as well as previews of what's next regarding the federal budget process.

3 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Microencapsulated drug delivery may soon revolutionize cancer treatment

Invasive and systemic cancer treatment is a necessary evil for many people with the devastating diagnosis. These patients endure therapies with ravaging side effects, including nausea, immune suppression, hair loss and even organ failure, in hopes of eradicating cancerous tissues in the body.

3 Mar 2014

Maximizing imaging techniques to bridge the gap between diagnosis and treatment of cancer

Glioblastoma multiforme is the most common form of brain cancer and patients with this diagnosis have a life expectancy of less than two years. In spite of the fact that its diagnosis is very good, an appropriate treatment remains elusive.

From Bruker BioSpin Division 3 Mar 2014

Photoreactive compounds open new routes to treatment of neurological diseases

Photoreactive compounds developed by scientists of Ludwig-Maximilians-Universitaet (LMU) in Munich directly modulate nerve-cell function, and open new routes to the treatment of neurological diseases, including chronic pain and certain types of visual impairment.

3 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

Viewpoints: The evolution of Medicare; generic drugs and patient safety; new food labels

About half a century ago, organized medicine and the hospital industry in this country struck a deal with Congress that in retrospect seems as audacious as it seems incredible: Congress was asked to surrender to these industries the keys to the United States Treasury. In return, the industries would allow Congress to pass a 1965 amendment to the Social Security Act .... We have come to know it as Medicare.

3 Mar 2014

Extract from amur cork tree shows promise in treating pancreatic cancer

The bark of the Amur cork tree (Phellodendron amurense) has traveled a centuries-long road with the healing arts. Now it is being put through its paces by science in the fight against pancreatic cancer, with the potential to make inroads against several more.

3 Mar 2014

WSU scientist receives grant to study effects of chronic methamphetamine on brain metabolism, sleep

WSU sleep scientist Jonathan Wisor has received a grant from the National Institutes of Health (NIH) to study the effects of chronic methamphetamine use on brain metabolism and sleep.

3 Mar 2014

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg.

3 Mar 2014

Bayer HealthCare joins NORD to promote awareness of Rare Disease Day

Bayer HealthCare is joining the National Organization for Rare Disorders (NORD) and others in raising awareness of Rare Disease Day, which is being celebrated today around the world.

3 Mar 2014

Perrigo Company acquires basket of value-brand OTC products in Australia

Perrigo Company plc announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. for $51 million in cash.

28 Feb 2014

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.

28 Feb 2014

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions today reported fourth quarter 2013 revenues of $585 million, compared to $750 million for the same quarter of 2012.

28 Feb 2014

Penn research team discovers new cost-effective way to fight rare blood disorder

A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.

28 Feb 2014

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein.

28 Feb 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

Pharmaceuticals News and Research

Akorn's consolidated revenue for fourth quarter 2013 increases 19% to $85 million

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

First Edition: March 3, 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Microencapsulated drug delivery may soon revolutionize cancer treatment

Maximizing imaging techniques to bridge the gap between diagnosis and treatment of cancer

Photoreactive compounds open new routes to treatment of neurological diseases

Scientists map key elements of immune overreaction triggered by influenza virus infection

Viewpoints: The evolution of Medicare; generic drugs and patient safety; new food labels

Extract from amur cork tree shows promise in treating pancreatic cancer

WSU scientist receives grant to study effects of chronic methamphetamine on brain metabolism, sleep

Actavis files ANDA with FDA to market Colchicine Tablets USP

Bayer HealthCare joins NORD to promote awareness of Rare Disease Day

Perrigo Company acquires basket of value-brand OTC products in Australia

Auxilium Pharmaceuticals’ net revenues increase $125.9M to 56%

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Penn research team discovers new cost-effective way to fight rare blood disorder

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

TSRI scientists describe severe immune overreaction caused by flu infections

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence